SEATTLE, March 2 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME) ("PBI"), a leading provider of specialized biomarker and contract research services, today announced that Ron Helm, Chief Executive Officer, will present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference. The conference will be held at the Ritz Carlton in Dana Point, California March 15-17, 2010.    

Mr. Helm is scheduled to present on Wednesday, March 17th at 10:00 a.m. Pacific Time, with one-on-one meetings scheduled for the same day.  Mr. Helm will discuss the expanding market opportunity for PBI as pharmaceutical and biotech companies seek to (1) design their human clinical trials to be more "adaptive" in nature with an increasing reliance on novel biomarkers, and (2) reduce the costs of developing and bringing to market new drugs and diagnostics.  A simultaneous webcast will be available at http://www.wsw.com/webcast/roth23/pbme/.

The three-day institutional investor conference will feature management presentations from over 350 small-cap public companies.  The broad spectrum of presenting companies will represent the following sectors:  Healthcare, Media & Internet, Enterprise Software, Gaming, Semiconductors, Global Energy and Industrials, and Retail & Consumer.

The conference is designed to provide investors with a unique opportunity to gain insights into small- and mid-cap growth companies and is expected to attract 2,500 attendees, including more than 1,500 institutional investors.  The event is formatted to maximize investor/company interaction through a combination of company presentations, Q&A sessions, expert panels and management one-on-one meetings.

For more information about this invitation-only event, please visit the conference website at www.roth.com or contact your ROTH representative at 800-933-6830.

About ROTH Capital Partners

ROTH Capital Partners is a full-service investment banking firm dedicated to the small-cap public market.  Since its inception in 1984, ROTH has been an innovator in this space.  ROTH has participated in underwriting IPOs for small-cap companies, has helped develop the PIPE financing structure, and has more recently become active in underwriting offerings from shelf registration statements.  ROTH was one of the first U.S. investment banks to focus on financing small-cap Chinese companies and established a Representative Office in Shanghai in 2007.

ROTH's experience and capabilities in raising capital for public companies are the hallmarks of the firm.  It has raised over $12.6 billion for public companies and completed approximately 160 merger and advisory assignments.  During 2009, ROTH assisted public companies in raising over $1.8 billion.  Visit the ROTH Capital Partners website at www.roth.com for additional information.  Member FINRA/SIPC.

About Pacific Biomarkers, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release includes forward-looking statements including, but not limited to, the following:  growth in revenues and backlog; results of business development activities; financial results; future growth; and the viability and acceptance of its established and new services, including the Company's biomarker services.  These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements.  These risks include, but are not limited to, the following:  the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).

SOURCE Pacific Biomarkers, Inc.

Back to top

RELATED LINKS
http://www.pacbio.com
http://www.roth.com